肝动脉与门静脉双介入治疗原发性肝癌的临床研究

Double interventional therapy through hepatic artery and portal vein in middle or advanced stage hepatocellular carcinoma of clinical application

目的研究与探讨肝动脉及门静脉双介入化疗栓塞对治疗原发性中晚期肝癌的可行性及临床疗效。方法 36例中晚期肝癌患者分为A、B两组,A组20例,成用肝动脉与门静脉双介入灌注化疗及栓塞(TACE+SPVE)方法治疗,B组16例,单纯采用肝动脉灌注化疗及栓塞(TACE)方法治疗。结果 A、B两组的近期有效率分别为90%和82.4%,治疗后0.5、1、2年生存率相比较,两组间差异有统计学意义(P<0.05)。两组并发症比较无统计学意义。结论应用肝动脉与门静脉双介入治疗原发性肝癌的效果,优于单纯肝动脉介入治疗,可显著提高患者的生命质量并延长生存周期,值得临床推广。

Objective To investigate the clinical research and effectiveness in double interventional therapy of mid- dle or advanced stage hepatocellular carcinoma through liver arterial and portal vein. Methods Total of 36 patients of middle or advanced stage hepat^ellular carcinoma divided into two groups. Group A double interventional therapy through liver arteri- al and portal vein chemotherapy and embolization was 20 patients. Group B alone interventional therapy through liver arterial chemotherapy and embolization was 16 patients. Results The short - term effective rate was and in group A and group B. There was a significant difference between the two groups （P 〈 0.05 ）. The half, 1 and 2 year survival rate were 85% ,75% and 55% in group A, but 76. 5% ,52.4% and 38. 1% in group B, There was a significant difference between the two groups （ P 〈 0. 05 ）. There was no marked difference in incidence rate of complications between the two groups （ P 〉 0. 05 ）. Conclu- sion The therapeutic effect of double interventinal therapy through liver arterial,and portal vein on middle or advanced stage hepatocellular carcinoma, is better than that of alone interventional therapy through liver arterial.